tbuckley/cabot-search huggingface dataset:
Abstract 16807: Burden and Timing of Hospitalizations in Heart Failure: A Community Study
Authors: Alanna M Chamberlain, Yariv Gerber, Shannon M Dunlay, Sheila M Manemann, Susan A Weston, Veronique L Roger
Journal: Circulation (2014)

Background: Heart failure (HF) patients are experiencing an epidemic of hospitalizations. Nevertheless, data on the frequency and distribution of hospitalizations over the course of the disease are lacking. Methods: We determined the rates of hospitalizations during periods of follow-up in Olmsted County, MN residents with incident HF from 2000-2010. HF was identified using ICD-9 code 428 and validated by the Framingham criteria. All hospitalizations were obtained for the 2 years following incident HF and each was categorized as due to HF, other cardiovascular (ICD-9 codes 390-427, 429-459), or non-cardiovascular causes. Follow-up was divided into discrete time periods (epochs): 0-30, 31-182, 183-365, and 366-730 days. Negative binomial regression examined associations between epochs of follow-up time and hospitalizations. Results: Among 1702 incident HF patients (mean age 76, 44% male), 1143 (67%) were hospitalized at index. Over the 2 year follow-up, 3008 hospitalizations were observed among 1136 patients, and 351 patients were hospitalized within 30 days of incident HF (median time from HF to hospitalization: 11 days). The majority of hospitalizations were due to non-cardiovascular causes (63% vs. 14% HF, 23% other cardiovascular); however, a larger proportion of HF and other cardiovascular hospitalizations were observed within the first 30 days (52% non-cardiovascular, 18% HF, 30% other cardiovascular) compared to the other time periods. The rate of hospitalization was highest within the first 30 days and was similar across sex, presentation of incident HF (inpatient, outpatient), and type of HF (preserved (≥50%), reduced (&lt;50%) ejection fraction) (Table). Conclusions: HF patients experience high rates of hospitalizations, particularly within the first 30 days, and the majority of hospitalizations are for non-cardiovascular causes. Continued efforts to manage comorbid conditions and reduce hospitalizations in HF patients are needed.
North Staffordshire Infirmary: Case of Exostosis of the Tibia, and Operation
Authors: J. Seddom
Journal: BMJ (1847)

About two years and a half ago, h4s attention was first called to a " lump" in the upper and back part of the right leg, by uneasiness in the prt, which was attended with occasional numbness in the ankle; there is no very marked swelling of the part, bnt the muscles of the calf, on examination, seem to be stretched, and a hard tumour can be felt firmly attached to the upper and posterior part of the tibia.A pulsating blood-vsssel can be traced on the outer edge of the tumour.The patient thinks the swelling may have been caused by leaping.Leeches, blisters, and other measures had been resorted to before his admission.He was directed to take Potassii lodidi, ,gr.iv., twice a day, and he had a strong compound iodine
Abstract 16744: Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and All-Cause 30-Day Readmissions in Medicare-Eligible Patients With NYHA Class III Heart Failure: Results From the CHAMPION Trial
Authors: Philip B Adamson, William T Abraham, Jordan Bauman, Jay Yadav
Journal: Circulation (2014)

Introduction: Heart failure (HF) is the most frequent discharge diagnosis for hospitalized Medicare beneficiaries. Readmission after a HF hospitalization (HFH) is an important metric for quality of care. Under the Hospital Readmissions Reduction Program (HRRP), hospitals with excess all-cause 30-day readmissions may be penalized for inadequate quality of care. Results from the CHAMPION trial confirmed that HF management using pulmonary artery pressure (PAP) monitoring from an implanted sensor in patients with NYHA Class III HF reduced HFH rates compared to standard management. However, the impact of this strategy on HFH rates and all-cause 30-day readmissions in Medicare-eligible patients is unknown. Methods: Retrospective analyses of patients 65 years or older at baseline in the CHAMPION trial were performed. HFH rates and 30-day readmissions in this subgroup were compared. Excess readmission ratios reported by the HRRP were then compared with the CHAMPION readmission ratio resulting from PAP monitoring. Results: 245 patients in CHAMPION (45%) were 65 years or older at the time of PA sensor implantation (120 in the Treatment group and 125 in the Control group). Patients in the Treatment group managed with PAP monitoring had a significantly lower HFH rate (60 HFH, 0.34/year) compared to the Control group (117 HFH, 0.67/year) (IRR 0.51, 95% CI 0.37-0.70, p&lt;0.0001). The Treatment group had a significantly reduced 30-day readmissions rate (13 readmissions, 0.07/year) compared to the Control group (31 readmissions, 0.18/year) (IRR 0.42, 95% CI 0.20-0.82, p=0.006). Using index HFH as the unit of observation for 30-day readmissions, the Treatment group ratio (13 readmissions/56 index HFH, 23.2%) was lower than the Control group ratio (31 readmissions/99 index HFH, 31.3%). PAP monitoring resulted in a CHAMPION readmission ratio (23.2%/31.3%, 0.74) that was lower than all hospital excess readmission ratios reported in the 2011 HRRP dataset. Conclusions: HF management incorporating PAP monitoring significantly reduced HFH rates and all cause 30-day readmissions in Medicare-eligible patients. Adoption of this treatment strategy at hospitals struggling with HFH and 30-day readmissions could help address an unmet need within the US health care system.
Dianhydrogalactitol (NSC-132313): Pharmacokinetics in Normal and Tumor-Bearing Rat Brain and Antitumor Activity Against Three Intracerebral Rodent Tumors 2
Authors: V. A. Levin, M. A. Freeman Dove, C. E. Maroten
Journal: JNCI Journal of the National Cancer Institute (1976)

Dianhydrogalactitol (DAG; NSC-132313), a hexitol epoxide, was used to treat intracerebral rodent tumors. DAG was most active against the murine ependymoblastoma [treated/controls (T/C)greater than 440%], less active against murine glioma 26 (T/C approximately 112-150%), and least active against rat 9L gliosarcoma (T/C approximately 100%). Application of a two-compartment open model for plasma disappearance of 14C-DAG in rats gave a volume of distribution at steady state of approximately 872 ml, a clearance of approximately 9.4 ml/minute, and an elimination constant of 0.025/minute. Entry of 14C-DAG was more rapid into the 9L tumor than into the normal brain. When a two-compartment series model for brain and tumor entry was applied, the t1/2 (half-time) for compartmental equilibrium was approximately 22 and 105 minutes in the brain, and 4 and 56 minutes in the 9L tumor. The drug rapidly entered the brain and tumor intracellular compartments. Binding to RNA was linear with time, and the absolute amount of binding was approximately six times greater for RNA than for DNA.
Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease
Authors: Ezgi Demirdogen Cetinoglu, Asli Gorek Dilektasli, Esra Uzaslan, Ahmet Ursavas, Ercument Ege
Journal: European Respiratory Journal (2014)

Purpose:ILD patient's oxygenation should be asses at baseline and during follow-up evaluation. The increase in the red cell distribution width (RDW)is independent predictors of coronary thrombus burden and associated with increased mortality risk in patients with respiratory insufficiency.Our aim was to evaluate the correlation between hypoxemia and age, length of stay hospital,biochemical parameters, RDW, in-hospital mortality in patients with ILD.

Method:A retrospective study was conducted on 184 patients who hospitalized for diffuse ILD in Pulmonary Department between 2010-2013.

Results:The mean age of the patients was 62±13 and 51% were female. Patients were classified according to their partial oxygen pressure (PO2) values; 7% of the patients were severe hypoxemia (< 40mmHg), while 20%were moderate hypoxemia (40-59mmHg), 18% were mild hypoxemia and 23%were non hypoxemic. In patients with severe or moderate hypoxemia white blood cells count was higher and pH values were lower than those who were not hypoxemics(p=0.004,p=0.005,p=0.001,p=0.003respectively). The RDW level had a mean value of 16.7±2.8 and RDW values were significantly higher in severe hypoxemic patients than the patients had no hypoxemia(p=0.009).No significant correlation was observed between PaO2 levels of ILD patients and age, length of stay in hospital, biochemical parameters on admission and in-hospital mortality.

Conclusion: Diffuse ILD seems to occur in elderly patients and hypoxemia can be observed during hospitalization. Although no correlation was observed between level of hypoxemia and length of stay in hospital or mortality,high RDW levels in severe hypoxemic patients may be secondary to right heart failure.
Generalized verrucosis and HPV-3 susceptibility associated with CD4 T-cell lymphopenia caused by inherited human interleukin-7 deficiency
Authors: Liran Horev, Susanne Unger, Vered Molho-Pessach, Tomer Meir, Alex Maly, Polina Stepensky, Mariana Zamir, Baerbel Keller, Sofia Babay, Klaus Warnatz, Yuval Ramot, Abraham Zlotogorski
Journal: Journal of the American Academy of Dermatology (2015)
MALT lymphomas and Helicobacter pylori? Reply
Authors: S A H. CANN
Journal: Gut (2001)

Editor,—Raderer et al (Gut2000;46:133–5[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4]) present an interesting case report of a patient with a mucosa associated lymphoid tissue (MALT) lymphoma of the stomach and descending colon. Their report adds to the growing literature of gastrointestinal MALT lymphomas that respond to antibiotic treatment. In addition to the numerous reports on antibiotic sensitive gastric lymphomas,1 those of the small intestine,2 salivary glands,3 ,4 nasal mucosa,5 and colon6 ,7 have recently been reported. Although Helicobacter pylori is generally implicated as the inducing agent, this does not always appear to be the case. A related bacterium, H heilmannii … Professor M Raderer. markus.raderer{at}akh-wien.ac.at [1]: {openurl}?query=rft.jtitle%253DGastrointestinal%2Bendoscopy%26rft.stitle%253DGastrointest%2BEndosc%26rft.aulast%253DNg%26rft.auinit1%253DW.%2BW.%26rft.volume%253D51%26rft.issue%253D1%26rft.spage%253D93%26rft.epage%253D96%26rft.atitle%253DRegression%2Bof%2Bhigh-grade%2Bgastric%2Bmucosa-associated%2Blymphoid%2Btissue%2Blymphoma%2Bwith%2BHelicobacter%2Bpylori%2Bafter%2Btriple%2Bantibiotic%2Btherapy.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0016-5107%252800%252970399-3%26rft_id%253Dinfo%253Apmid%252F10625811%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1016/S0016-5107(00)70399-3&link_type=DOI [3]: /lookup/external-ref?access_num=10625811&link_type=MED&atom=%2Fgutjnl%2F48%2F2%2F283.2.atom [4]: /lookup/external-ref?access_num=000084767200026&link_type=ISI
Bone-Marrow-Resident NK Cells Prime Monocytes for Regulatory Function during Infection
Authors: Michael H. Askenase, Seong-Ji Han, Allyson L. Byrd, Denise Morais da Fonseca, Nicolas Bouladoux, Christoph Wilhelm, Joanne E. Konkel, Timothy W. Hand, Norinne Lacerda-Queiroz, Xin-zhuan Su, Giorgio Trinchieri, John R. Grainger, Yasmine Belkaid
Journal: Immunity (2015)
Dental and Oral Radiography. A Textbook for Students and Practitioners of Dentistry.
Authors: James David McCoy
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P2-13-18: Oncologic outcome of 2,217 patients with breast cancer after negative sentinel lymph node biopsy without axillary lymph node dissection
Authors: Jong Tae Park, Hak Min Lee, Sung Gwe Ahn, Seung Ah Lee, Joon Jeong
Journal: Cancer Research (2015)

Abstract Background Sentinel lymph node biopsy (SLNB) is a standard method for nodal staging and enables to omit axillary lymph node dissection after negative sentinel lymph node (SLN). False-negative rate of SLNB has been reported as 5-7%. To dissolve the concerns regarding the axillary recurrence due to false-negative cases after negative SLNB, we investigated oncologic outcomes of a large number of breast cancer patients with negative SLN after SLNB. Methods A total of 2,475 patients with clinically node-negative breast cancer underwent SLNB at Severance hospitals between December 1998 and December 2013. 99-m Tc radiocolloid or blue dye was used in SLNB with periareolar intradermal injection technique. Intraoperative frozen examination of SLN was performed. If frozen test for SLN showed negative result, further axillary node dissection was omitted. Survival rates were estimated by the Kaplan-Meier method. Multivariate survival analysis was performed using the Cox-regression hazard model. Results Among 2,475 patients, 2,217 patients had no metastatic focus on SLN. A mean of 2.4 sentinel lymph nodes was dissected in all of the patients. At a median follow-up of 36 months, only 13 patients (0.6%) had axillary recurrence, and a median time to the recurrence was 20 months (range 7-45 months). During the follow-up period, 22 local, 16 regional, and 44 distant recurrences were observed. In multivariate analysis for axillary recurrence, tumor size and refusal of systemic therapy were demonstrated to be independent risk factors for axillary recurrence (hazard ratio (HR) 1.77, 95% confidence interval (CI), 1.08-2.89, P=0.024; HR 0.15, 95% CI, 0.03-0.75, P=0.021). Disease-free survival and axillary recurrence-free survival rates at 3 years were 96.5% (95% CI, 0.960-0.970) and 99.2% (95% CI, 0.990-0.994), respectively. Conclusions The axillary recurrence rate was very low in patients with negative SLN. Our findings supported that SLNB is a reliable procedure and its oncologic safety is not affected by the chance of axillary recurrence after negative SLNB. Citation Format: Jong Tae Park, Hak Min Lee, Sung Gwe Ahn, Seung Ah Lee, Joon Jeong. Oncologic outcome of 2,217 patients with breast cancer after negative sentinel lymph node biopsy without axillary lymph node dissection [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-13-18.
Abstract 18105: Comparison of Efficacy and Safety of Two Dosages Dabigatran versus Warfarin in Patients with Persistent and Long-standing Atrial Fibrillation Undergoing Electrical Cardioversion
Authors: Oskars Kalejs, Olga Litunenko, Sandis Sakne, Aldis Strelnieks, Marina Kovalova, Galina Dormidontova, Iveta Sime, Maija Vikmane, Milana Zabunova, Vita Saripo, Aivars Lejnieks, Andrejs Erglis
Journal: Circulation (2014)

Introduction: The most important factor for efficacy and safety for patients with atrial fibrillation (AF) undergoing electrical cardioversion (ECV) is appropriate use of oral anticoagulant (OAC) therapy. Dabigatran is a possible alternative OAC therapy before and after ECV versus therapy with warfarin. Methods: We have analysed the data collected before, during and after ECV in 1046 patients (pts) undergoing ECV. All pts had AF, 885 defined as persistent and 161 defined as long-acting, mean CHA2DS2 VASc score was 3.1 ± 1.8, 735 had one or two ECV in anamnesis. 628 (60%) pts started the use of dabigatran, (405 pts 150 mg twice or 223 pts 110 mg twice) before ECV for at least 21 day, 418 (40%) started warfarin therapy, 21 day start after INR was in range 2.0 - 3.0. Transesophageal echocardiography (TEE) was encouraged before ECV in all groups for pts with CHA2DS2VASc score ≥ 3, markedly left atrial dilatation and AF duration ≥ 6 months. ECG and Echo-kg data were analysed 30 and 90 days after ECV. Results: ECV was successful after first shock in 962 (91.7%) pts, in total successful ECV - in 1029 (98.37%) pts. Left atrial thrombi were detected on TEE before ECV in 7 pts in dabigatran group and 12 pts in warfarin group, so, pts continued OAC therapy for one month, and TEE had been performed again. 3 pts in dabigatran (150 mg twice) group and 2 pts in warfarin group were free of thrombus and have been referred to ECV. Average time for treatment before ECV was significantly lower for dabigatran (25 days) vs warfarin (44 days, p&lt;0.01). Stroke and systemic embolism rates at 90 days were lower in both dabigatran group (0.1%) vs warfarin group (1.4%). There was no difference in analysis of events between TEE and non-TEE pts. Dabigatran pts had significantly lower clinical relevant bleeding rate vs warfarin (D 110 mg 0, D 150 mg 0.47% vs W 2.87%, p&lt;0.04). Conclusions: Dabigatran 150 mg and 110 mg twice is a safe, effective and reasonable alternative to warfarin for patients undergoing ECV despite CHA2DS2VASc risk score and AF duration. The frequencies of stroke and embolic events were lower in dabigatran 150 mg and 110 mg versus warfarin with lower bleeding rates within 30 and 90 days after ECV. Patients undergoing dabigatran therapy have shorter time before procedures and can save time for INR test in normal range.
The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORγt and Controls Metabolic Disease
Authors: Lucile Garidou, Céline Pomié, Pascale Klopp, Aurélie Waget, Julie Charpentier, Meryem Aloulou, Anaïs Giry, Matteo Serino, Lotta Stenman, Sampo Lahtinen, Cedric Dray, Jason S. Iacovoni, Michael Courtney, Xavier Collet, Jacques Amar, Florence Servant, Benjamin Lelouvier, Philippe Valet, Gérard Eberl, Nicolas Fazilleau, Victorine Douin-Echinard, Christophe Heymes, Rémy Burcelin
Journal: Cell Metabolism (2015)
Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease
Authors: James Shepherd, John J.P. Kastelein, Vera Bittner, Prakash Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea Zuckerman, Nanette K. Wenger
Journal: Journal of the American College of Cardiology (2008)
Funding, Advances Invigorate TB Fight
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 13171: Cellular Basis of Angiotensin-(1-7) Produced Augmentation on Left Ventricular Contractile Function in Heart Failure
Authors: Xiaowei Zhang, Heng-Jie Cheng, Peng Zhou, Tiankai Li, Wei-Min Li, Che Ping Cheng
Journal: Circulation (2014)

Background: Accumulating evidence suggests that Angiotensin (A)-(1-7) exhibits cardiovascular effects that are in opposition to that of AII, thus providing protection against heart diseases. However, the exact means by which A-(1-7) affords cardioprotection are unclear. Its direct cardiac effect is not well understood. We previously showed that in heart failure (HF), AII decreases left ventricle (LV) contractility. Whether A-(1-7) may antagonize AII-induced cardiac depression, thereby contributing to its beneficial actions in HF remains to be determined. We assessed the hypothesis that A-(1-7) may produce positive modulation on [Ca 2+ ] i regulation and LV and myocyte contraction via A-(1-7) receptors, coupled with nitric oxide (NO)/bradykinin (BK)-mediated mechanism. Methods: We measured LV contractility changes after A-(1-7) (650 ng/kg, iv), which produced a 20-fold increase in plasma A-(1-7) levels, mimicking the elevations caused by angiotensin-converting enzyme inhibitor therapy in HF, and compared myocyte contractile, [Ca 2+ ] i transient ([Ca 2+ ] iT ) and I Ca,L responses to A-(1-7) (10 -5 M) in 14 rats with isoproterenol induced HF (3 months after 170 mg/kg sq for 2 days). In the subsets of cell contractile study, myocytes were pretreated to inhibit NO synthase (L-NAME, 10 -5 M), BK (HOE 140, 10 -6 M) or A-(1-7) receptor [D-Ala 7 ]-A-(1-7), 10 -5 M) followed with A-(1-7) exposure. Results: Compared with baseline, after A-(1-7), E ES (47%, 1.0 vs 0.68 mmHg/μl) and M SW (49%, 94.3 vs 62.8 mmHg) were increased, indicating enhanced LV contractility. In HF myocytes, A-(1-7) increased myocyte percent shortening (28%, 6.8% vs 5.3%), the velocity of contraction (31%, 106.4 vs 74.5 μm/sec) and relengthening (41%, 74.7vs 50.1 μm/sec) accompanied by significantly-increased [Ca 2+ ] iT (27%, 0.19 vs 0.15 pA/pF) and I Ca,L (24%, 6.3 vs 5.1pA/pF). L-NAME increased, HOE 140 decreased, and A-(1-7) receptor blockade prevented myocyte contractile responses to A-(1-7). Conclusion: In HF, clinically-relevant concentrations of A-(1-7) counteracted AII-induced cardiac depression, increased [Ca 2+ ] iT and I Ca,L , and produced positive inotropic effects in both LV and myocytes. These effects are coupled with A-(1-7) receptors and involve activation of NO/BK pathways.
Feeding and the Nutritional Disorders in Infancy and Childhood.
Authors: Julius H. Hess
Journal: JAMA (1926)

This popular book, as revised, takes into account the developments in the field of artificial feeding of infants during the past two years. Diets have been added for children up to and including the sixth year, and the chapters dealing with rickets, scurvy, spasmophilia, acidosis and anemia have been especially reviewed in the light of recent knowledge. A special chapter on celiac disease is a well illustrated and competent addition. The book is excellently printed and full of hints for the general practitioner who gives attention to the diseases of children.